Clinical Trial Results of the BCMA CAR-T Co-developed by Innovent and IASO Biotherapeutics Commented in American Society of Hematology’s Medical Journal “Blood”
SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2021 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”, HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, together with IASO Biotherapeutics (IASO Bio), today jointly announced that the results of initial clinical studies on treatment of relapsed or refractory multiple myeloma (R/R MMin subjects using…
